News & Media

“This study shows that when we remove barriers to care and apply precision medicine equitably, we can improve outcomes for all patients,” said senior author Kara Maxwell, MD, PhD, director of the Men & BRCA program.

Experts from across oncology specialties shared some of the most talked-about abstracts and discussions from the 2025 AACR Annual Meeting, including Ronny Drapkin, MD, PhD, Director of Gynecologic Cancer Research at the Basser Center.

The BRCA mutation is five times more common in the Jewish community, especially among Ashkenazi Jews. “Increasing awareness of genetic testing could help avoid deaths from hereditary cancers,” said Susan Domchek, MD, Basser's executive director.

Ronny Drapkin, MD, PhD, Basser's Director of Gynecologic Cancer Research, will present on multiomics approaches to finding new biomarkers that can be leveraged for early detection at the 2025 AACR Annual Meeting.

In recognition of her contributions to cancer prevention and control research, Susan Domchek, MD has been selected to receive this year’s ASCO-American Cancer Society Cancer Prevention Award, which will be presented at the 2025 ASCO Annual Meeting.

Motivated by generations past, present, and future, two patients participating in the first-of-its-kind clinical trial testing an experimental approach to stop cancer in its tracks at the earliest stages of development at the Basser Center for BRCA.

Basser cancer and surgery specialists Drs. Kara Maxwell, Daniel Lee, Jennifer Zhang, and Bryson Katona delve into the nuances of BRCA-positive breast, prostate, and pancreatic cancers in men.

Basser executive director Susan M. Domchek, MD and Abramson Cancer Center director Robert H. Vonderheide, MD, DPhil have been elected as Fellows of the 2025 American Association for Cancer Research (AACR) Academy.

Katherine Nathanson, MD discusses the impact of reversion mutations on resistance to PARP inhibitors across various DNA damage repair genes.

Katherine Nathanson, MD, director of Genetics at the Basser Center, discussed next steps for identifying how breast cancers become resistant to treatment.